The Bruker Microbiology & Infection Diagnostics division has announced the European launch of its MyGenius PRO automated sample-to-answer (S2A) molecular diagnostics system at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026.
The platform is designed for infectious disease diagnostics and features polymerase chain reaction technology.
It supports higher throughput operations, continuous sample loading, and random-access functions, automating the full workflow from patient sample to diagnostic result and supporting laboratories that require increased efficiency and testing capacity.
MyGenius PRO has already been installed at a European transplant centre, where it is being used for routine infectious disease testing.
At launch, the system’s in vitro diagnostic regulation (IVDR) menu will include assays for cytomegalovirus (CMV) and Epstein-Barr virus (EBV) from whole blood, as well as BK virus (BKV) from urine. These assays are tailored to support diagnostics in immunocompromised patients.
Bruker has planned further menu expansion throughout this year to include human immunodeficiency virus type 1 (HIV-1), hepatitis B virus (HBV), hepatitis C virus (HCV), human herpesvirus 6 (HHV-6) IVDR assays, and more sample matrices.
The MyGenius PRO development was a collaboration between Bruker company ELITechGroup and Hitachi High-Tech, merging molecular assay, automation, and engineering expertise.
In Japan, Hitachi High-Tech will offer the platform as Labospect GA-5, which will utilise Bruker molecular diagnostic assays in accordance with Japanese diagnostic requirements.
This launch further extends Bruker’s molecular diagnostics portfolio, which includes InGenius, BeGenius, and LiquidArray assays.
Bruker continues to focus on providing solutions supporting molecular, cellular, and microscopic analysis in various research and diagnostic fields.
Earlier this year, Bruker Energy & Supercon Technologies (BEST) confirmed two multi-year MRI superconductor supply agreements with global healthcare companies, totalling approximately $500m in anticipated revenues.
